2022年4期
刊物介紹
本刊主要是及時報道我國在腫瘤防治研究領(lǐng)域包括癌癥基礎(chǔ)理論研究和癌癥預(yù)防、臨床治療研究方面的新進(jìn)展、新成果，內(nèi)容涉及腫瘤病因?qū)W與滸病學(xué)，實驗?zāi)[瘤學(xué)、腫瘤細(xì)胞分子生物學(xué)，腫瘤病理學(xué)以及腫瘤影像診斷、腫瘤外科治療、化學(xué)治療、放射治療、介入治療、生物治療和中西醫(yī)結(jié)合治療腫瘤等各分支學(xué)科，旨在促進(jìn)國內(nèi)外學(xué)術(shù)交流，提高我國癌癥研究與癌癥治療水平。
Chinese Journal of Cancer Research
NHCPRC Guidelines
Original Article
- Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
- Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world,multicenter,retrospective,controlled study in China
- Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer
- Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
- Development and validation of a predictive model for endocervical curettage in patients referred for colposcopy: A multicenter retrospective diagnostic study in China